Outcome of acute lymphoblastic leukemia treatment using national protocols at the Queen Sirikit National Institute of Child Health.
OBJECTIVE
To evaluate the outcome of acute lymphoblastic leukemia (ALL) treatment at the Queen Sirikit National Institute of Child Health (QSNICH) after using national protocols.


METHODS
Seventy-six pediatric patients with newly diagnosed with ALL, who were treated in Queen Sirikit National Institute of Child Health using the national protocols during March 2006 and February 2008, were enrolled. The national protocols were sub-classified by clinical risk factors and morphology of leukemic cells of the patients at initial presentation into 3 groups as standard risk (ALL-01-05), high-risk (ALL-02-05), and mature B-ALL or L3 (NHL-04-06) protocol. Overall survival (OS) and event-free survival (EFS) were determined by using Kaplan-Meier survival curves.


RESULTS
The overall survival rate of ALL patients treated using the national protocols was 83.85% (88.06% in standard group, 82.01% in high-risk group, and 75% in L3 protocol). The mortality rate and event-free survival of ALL patients was 13.33% and 72.50%, respectively.


CONCLUSIONS
The national protocols for ALL showed benefit in the improvement of outcomes from treatment in childhood ALL.
Somjai
S
Kanjanapongkul
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D009364:Neoplasm Recurrence, Local; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome